title: Recombinant lactic acid bacteria as mucosal biotherapeutic agents.
abstract: The safety status of lactic acid bacteria (LAB) and their capacity to survive the passage through the gastrointestinal tract (GI tract) have rendered them excellent candidates for the production of therapeutic proteins and their delivery in situ to the GI tract. During the past two decades, major health benefits of mucosally administered recombinant LAB have been successfully demonstrated, predominantly using animal models. However, the field has recently moved into the era of human clinical trials. In this review, we provide a timely update on the recent important advances made in this field, and outline the potential of recombinant LAB as therapeutic tools for their safe and efficient use in human health.
authors.affiliation: Institut Pasteur de Lille, Center for Infection and Immunity of Lille, Université Lille Nord de France, CNRS, UMR 8204, Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France. catherine.daniel@ibl.fr
authors.forename: Catherine
authors.initials: C
authors.lastname: Daniel
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Roussel
authors.forename: Michiel
authors.initials: M
authors.lastname: Kleerebezem
authors.forename: Bruno
authors.initials: B
authors.lastname: Pot
mesh_terms: D058956:Administration, Mucosal; D000818:Animals; D016503:Drug Delivery Systems; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D005818:Genetic Engineering; D006801:Humans; D007413:Intestinal Mucosa; D056546:Lactobacillales / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics
chemical_list: D011994:Recombinant Proteins